Enovis Corporation/$ENOV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Enovis Corporation
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
Ticker
$ENOV
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
7,367
ISIN
US1940145022
Website
ENOV Metrics
BasicAdvanced
$1.8B
-
-$14.50
1.90
-
Price and volume
Market cap
$1.8B
Beta
1.9
52-week high
$49.38
52-week low
$29.13
Average daily volume
1.3M
Financial strength
Current ratio
2.552
Quick ratio
0.993
Long term debt to equity
54.068
Total debt to equity
54.832
Interest coverage (TTM)
0.96%
Profitability
EBITDA (TTM)
359.11
Gross margin (TTM)
60.08%
Net profit margin (TTM)
-37.65%
Operating margin (TTM)
3.55%
Effective tax rate (TTM)
-1.26%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
0.92%
Return on equity (TTM)
-27.35%
Valuation
Price to revenue (TTM)
0.796
Price to book
0.67
Price to tangible book (TTM)
-3.81
Price to free cash flow (TTM)
-43.891
Free cash flow yield (TTM)
-2.28%
Free cash flow per share (TTM)
-69.86%
Growth
Revenue change (TTM)
18.32%
Earnings per share change (TTM)
860.33%
3-year revenue growth (CAGR)
12.99%
10-year revenue growth (CAGR)
-7.08%
3-year earnings per share growth (CAGR)
124.79%
10-year earnings per share growth (CAGR)
4.30%
Bulls say / Bears say
Enovis Corporation has attracted significant institutional investment, with Boston Partners increasing its holdings by 27.1% during the fourth quarter, indicating strong confidence in the company's future prospects. (techdows.com)
The company's inclusion in the S&P SmallCap 600 index as of January 14, 2025, may enhance its visibility and attract more investors, potentially boosting stock value. (mlq.ai)
Enovis reported an adjusted EBITDA of $83.2 million for the first quarter of 2024, reflecting a 47.5% increase from the previous year, showcasing strong financial performance. (sec.boardroomalpha.com)
The planned CEO succession, with Matt Trerotola announcing his intention to retire, introduces uncertainty regarding future leadership and strategic direction. (mlq.ai)
Enovis reported a net loss from continuing operations of $71.8 million in the first quarter of 2024, a significant increase from the $22.8 million loss in the same period the previous year, indicating financial challenges. (sec.boardroomalpha.com)
The company's stock price has experienced volatility, with a 52-week range between $35.14 and $62.79, which may concern potential investors about stability. (techdows.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
ENOV News
AllArticlesVideos
Enovis to Participate in Upcoming Investor Conferences
GlobeNewsWire·2 weeks ago
Orthopedic Braces & Supports Market Focused Insights 2025-2030, with Key Vendor Profiles for BREG, Bauerfeind, DeRoyals, Enovis, Ottobock, Ossur and Tynor
GlobeNewsWire·4 weeks ago
Enovis Announces First Quarter 2025 Results
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Enovis Corporation stock?
Enovis Corporation (ENOV) has a market cap of $1.8B as of June 20, 2025.
What is the P/E ratio for Enovis Corporation stock?
The price to earnings (P/E) ratio for Enovis Corporation (ENOV) stock is 0 as of June 20, 2025.
Does Enovis Corporation stock pay dividends?
No, Enovis Corporation (ENOV) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Enovis Corporation dividend payment date?
Enovis Corporation (ENOV) stock does not pay dividends to its shareholders.
What is the beta indicator for Enovis Corporation?
Enovis Corporation (ENOV) has a beta rating of 1.9. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.